Navigation Links
ALTITUDE Clinical Data Show ICD Therapy Saves Lives Without Mortality Increase from Device Shock
Date:5/5/2011

NATICK, Mass. and SAN FRANCISCO, May 5, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of its ALTITUDE® Clinical Science program, which demonstrated that defibrillator therapy saves lives from lethal arrhythmias without an increase in mortality due to defibrillator shock.  Instead, the authors found that increased mortality risk associated with these shocks is not attributed to the defibrillator shock itself, but rather entirely related to the underlying medical condition leading to atrial and ventricular arrhythmias.

ALTITUDE analyzes outcomes data from patients monitored by the LATITUDE® Patient Management system.  Brian Powell, M.D., Assistant Professor of Medicine at the Mayo Clinic, presented results during a late-breaking trial session at the Heart Rhythm Society Scientific Sessions in San Francisco.

"The ALTITUDE Clinical Science program continues to provide groundbreaking data on survival after device implantation and has greatly advanced our understanding of the natural history of arrhythmias and how device programming influences patient outcomes," said Leslie Saxon, M.D., Chief of Cardiovascular Medicine at University of Southern California and chairperson of the ALTITUDE physician panel.  "What these data tell us is that patients who have atrial fibrillation or ventricular arrhythmias and receive shocks should be monitored and treated aggressively.  While shocks should only be delivered when necessary, it is encouraging to know that shock therapy from these devices does not increase mortality."

The ALTITUDE program enhances physician understanding of device therapy, outcomes and disease progression in a real-world setting for device patients followed by the LATITUDE® Patient Management system.  The system lets physicians conduct remote follow-up of implantable cardiac device patients to monitor specific device information and heart health status.  The system also detects clinical events between scheduled in-clinic visits and sends relevant data directly to physicians.  Since its introduction in 2006, Boston Scientific has enrolled more than 190,000 patients.  

Boston Scientific's latest implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) feature AcuShock™, an advanced technology that can distinguish between a potentially lethal heart arrhythmia and a non-lethal arrhythmia within seconds, which can help to minimize inappropriate and unnecessary shocks.

"Our devices deliver painless pacing therapy far more than shocks to treat potentially lethal arrhythmias, while demonstrating extremely low rates of inappropriate shocks," said Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management for Boston Scientific.  "Recent data from a large number of patients from our ALTITUDE program show that nearly 98 percent were free of an inappropriate first shock within the first year of therapy when physicians chose to use AcuShock features in our COGNIS® and TELIGEN® devices."

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.CONTACT:

Erik Kopp508-650-8660 (office)Media RelationsBoston Scientific Corporationerik.kopp@bsci.comSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific Corporationinvestor_relations@bsci.com
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Adeonas Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant
2. Clinical Site Services Expands to Provide Global Patient Enrollment Services to Rest-of-World
3. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
4. Omnicare Clinical Research Acquired by Nautic Partners, LLC
5. Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability
6. ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration
7. Tissue Genesis Begins FDA-Approved Clinical Trial
8. ClearCanvas Releases First Commercial Version of Popular Clinical Radiology Workstation; PACS and RIS to Follow
9. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
10. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
11. ePharmaSolutions Launches New Application to Streamline Single Sign-On and User Account Provisioning for Sponsors Using Multiple Clinical Trial Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... ... August 11, 2017 , ... Algenist continues to disrupt ... unlocking collagen like never before. , Collagen is the key structural element skin ... with Liquid Collagen™, which include: , First to market ...
(Date:8/10/2017)... ... August 09, 2017 , ... Teachers from three Philadelphia ... August 14th through the 16th, the University City Science Center will kick off ... 2016, provides Philadelphia-based middle school educators an opportunity for professional development related to ...
(Date:8/10/2017)... , ... August 09, 2017 , ... Okyanos Center for ... place at the Pelican Bay Hotel in Freeport, Grand Bahama on September 27, 2017. ... required. , With oversight from the Ministry of Health’s National Stem Cell Ethics ...
(Date:8/10/2017)... UK (PRWEB) , ... August 10, 2017 , ... ... announced an agreement establishing Kinokuniya Company Ltd. as its exclusive sales representative for ... exclusive sales representative for the SPIE Digital Library in Japan. , “We look ...
Breaking Biology Technology:
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Biology News(10 mins):